EUCTR2016-004550-15-BEActive, not recruitingPhase 1
A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 1,500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Male or female of non-childbearing potential
- •- At least 50 years of age or older
- •- Weight 40 kg to 150 kg
- •- Medically appropriate for postoperative anticoagulant prophylaxis
- •- Has undergone an elective primary unilateral TKR
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 500
Exclusion Criteria
- •- Any condition for which the use of apixaban is not recommended in the opinion of the investigator
- •- Bilateral, revision or unicompartmental procedure
- •- Known or suspected hypersensitivity or intolerance to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or any of the excipients of JNJ-64179375
- •- Unable to undergo venography
- •- Known previous DVT in either lower extremity
- •- Any preplanned invasive procedure (eg, surgery, colonoscopy) up to Week 18 for which anticoagulant or antiplatelet therapy would be interrupted
- •- Planned use of intermittent pneumatic compression after randomization
Investigators
Similar Trials
Active, not recruiting
Phase 1
A 2-Part Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee ReplacementThromboembolism in subjects who have undergone an elective primary unilateral total knee replacementEUCTR2016-004550-15-LVJanssen-Cilag International NV1,500
Unknown
Phase 2
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement SurgeryVTE prophylaxis with anticoagulation after Total Knee Replacement surgeryJPRN-jRCT2080223833Janssen Pharmaceutical K.K.150
Active, not recruiting
Phase 1
A 2-Part Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee ReplacementThromboembolism in subjects who have undergone an elective primary unilateral total knee replacementMedDRA version: 20.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865EUCTR2016-004550-15-PTJanssen-Cilag International NV1,500
Active, not recruiting
Phase 1
A 2-Part Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee ReplacementEUCTR2016-004550-15-ROJanssen-Cilag International NV305
Active, not recruiting
Phase 1
A 2-Part Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee ReplacementEUCTR2016-004550-15-PLJanssen-Cilag International NV1,500